Stocks · News reference
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal
Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 16, 2026, 4:35 PM
- Checked
- Jul 16, 2026, 4:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
Read original at benzingaCoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.
Read original at benzingaDeutsche Bank Downgrades AtaiBeckley to Hold, Lowers Price Target to $8
Deutsche Bank analyst David Hoang downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Hold and lowers the price target from $12 to $8.
Read original at benzingaObesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.
Read original at benzingaEli Lilly Stock Pulls Back After Hitting Record Highs Last Week
Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.
Read original at benzinga